Compare Elantas Beck with Similar Stocks
Stock DNA
Specialty Chemicals
INR 7,293 Cr (Small Cap)
50.00
42
0.08%
-0.66
14.48%
7.22
Total Returns (Price + Dividend) 
Risk Adjusted Returns v/s 
Returns Beta
News

Elantas Beck India Ltd is Rated Sell
Elantas Beck India Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 Sep 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 22 May 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news articleAre Elantas Beck India Ltd latest results good or bad?
Elantas Beck India Ltd's latest financial results for the quarter ended March 2026 reveal a mixed operational performance. The company reported a quarterly revenue of ₹222.17 crores, reflecting a sequential growth of 3.24% and a year-on-year increase of 7.78%. This indicates a continued demand for its electrical insulation products, marking the highest quarterly sales in its recent history. However, the net profit for the same period was ₹31.08 crores, which represents a significant decline of 21.01% from the previous quarter's profit of ₹39.37 crores, raising concerns about the sustainability of profit margins. The operating margin, excluding other income, contracted to 19.51%, down from 20.90% in the previous quarter, while the profit after tax (PAT) margin also saw a notable decrease to 13.99%, down from 18.29%. This margin compression is attributed to various operational challenges, including a sharp d...
Read full news article
Elantas Beck India Q4 FY26: Premium Valuation Tested as Quarterly Profit Dips Despite Revenue Growth
Elantas Beck India Ltd., the specialty chemicals manufacturer and subsidiary of Germany-based Elantas GmbH, reported a mixed performance for Q4 FY26, with net profit declining 15.90% quarter-on-quarter to ₹31.08 crores despite revenue reaching a fresh quarterly high. The stock has declined 2.92% following the results announcement, trading at ₹9,313.70 as investors grapple with the company's premium 52x price-to-earnings valuation amidst moderating profitability trends.
Read full news article Announcements 
Corporate Actions 
No Upcoming Board Meetings
Elantas Beck India Ltd has declared 75% dividend, ex-date: 05 May 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 3 Schemes (12.23%)
Held by 6 FIIs (0.04%)
Elantas Gmbh (75.0%)
Nippon Life India Trustee Ltd-a/c Nippon India Small Cap Fund (8.4%)
9.18%
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ
QoQ Growth in quarter ended Mar 2026 is 3.24% vs -0.62% in Dec 2025
QoQ Growth in quarter ended Mar 2026 is -21.06% vs 8.58% in Dec 2025
Half Yearly Results Snapshot (Standalone) - Jun'25
Growth in half year ended Jun 2025 is 13.07% vs 7.35% in Jun 2024
Growth in half year ended Jun 2025 is -8.38% vs 20.30% in Jun 2024
Nine Monthly Results Snapshot (Standalone) - Sep'25
YoY Growth in nine months ended Sep 2025 is 14.70% vs 8.99% in Sep 2024
YoY Growth in nine months ended Sep 2025 is -1.28% vs 9.50% in Sep 2024
Annual Results Snapshot (Standalone) - Dec'25
YoY Growth in year ended Dec 2025 is 13.27% vs 10.09% in Dec 2024
YoY Growth in year ended Dec 2025 is 5.89% vs 1.65% in Dec 2024






